|
|
BOARD OF DIRECTORS
Stephanie O'Brien represents Morningside Ventures and has extensive experience working with venture-backed technology companies. She focuses on early-stage companies, working with CEOs on building the management team and developing business plans. She has served on numerous private company boards, including ViOptiox, Inc., I-Behavior, Inc., Natural Polymer International Corp., Serica Technology, Inc., Alacer Biomedical, Inc., Inimex Pharmaceuticals, Inc. and BiddingForGood, Inc. She received her A.B., cum laude, from Harvard College and her J.D. from New York University School of Law. Prior to attending law school, Stephanie worked for Chase Manhattan Bank, N.A, where she completed the loan officer credit training program and then worked in international portfolio analysis. After law school, Stephanie spent nine years as a corporate lawyer with Hale and Dorr in the Boston and Washington, D.C. offices, working primarily with venture capital finance and start-up companies.
 William M. Greenman has an extensive history with the Cerus Corporation, the company from which Aduro acquired its Listeria vaccine technology platform. He is currently President and CEO of Cerus, having previously been the Chief Business Officer and Senior Vice President, Business Development and Marketing. From 2006 until August 2008, he served as President, Cerus Europe, where he established Cerus’ commercial presence in Europe, the Middle East and Africa. From 1999 to 2006, he served as Vice President, Business Development, during which time he played an instrumental role in the development of the Listeria vaccine program. Prior to joining Cerus in 1995 as Director of Business Development, he worked in various marketing and business development positions in Baxter’s Biotech Division from 1991 to 1995. Mr. Greenman has undergraduate degrees in Biological Sciences and Economics from Stanford University.
 Ross Haghighat, Triton Systems, Inc.
Ross Haghighat is a serial entrepreneur with nearly 25 years of experience in founding and transforming companies in the high tech fields of telecommunications, military electronics, biotechnology, and specialty materials.
He is the founding CEO of Triton Systems, headquartered in Chelmsford, Massachusetts. Mr. Haghighat serves on the Board of Directors of Triton Systems, S12 Technologies and FRX Polymers. He co-founded Coretek, Inc., a photonic-based telecom device company that was acquired by a Fortune 100 company in a billion dollar plus deal in 2001.
 Stephen T. Isaacs is Chairman and CEO of Aduro. Prior to Aduro, Mr. Isaacs was founder, President and CEO of Cerus Corporation (NASD:CERS), and grew Cerus from three employees to over two hundred and fifty, took Cerus public and developed two marketed products.
Prior to Cerus, Mr. Isaacs held a non-teaching faculty position at the Department of Chemistry at UC Berkeley, where he published over 20 articles and 40 patents. Mr. Isaacs holds a BA degree in Biochemistry from the University of California at Berkeley.
 Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon), University of California, San Francisco
Frank McCormick, Ph.D., F.R.S., D.Sc. (Hon) is the Director of the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, a multidisciplinary research and clinical care organization that is one of the largest cancer centers in the Western United States, and he is Associate Dean of the UCSF School of Medicine. A native of Cambridge, England, Dr. McCormick received his B.Sc. in biochemistry from the University of Birmingham (1972) and his Ph.D. in biochemistry from the University of Cambridge (1975). Postdoctoral fellowships were held in the US at the State University of New York at Stony Brook and in London at the Imperial Cancer Research Fund.
He has been a Fellow of the Royal Society since 1996. Prior to joining the UCSF faculty, Dr. McCormick pursued cancer-related work with several Bay Area biotechnology firms, including positions with Cetus Corporation (Director of Molecular Biology, 1981-90; Vice President of Research, 1990-91) and Chiron Corporation, where he was Vice President of Research from 1991-92.
In 1992 he founded Onyx Pharmaceuticals and served as its Chief Scientific Officer until 1996. Dr. McCormick's current research interests center on the fundamental differences between normal cells and cancer cells that can allow the development of novel therapeutic strategies.
In addition to his positions as Director of the UCSF Helen Diller Family Comprehensive Cancer Center and Associate Dean of the UCSF School of Medicine, he holds the E. Dixon Heise Distinguished Professorship in Oncology and the David A. Wood Distinguished Professorship of Tumor Biology and Cancer Research in UCSF's Department of Microbiology and Immunology. Dr. McCormick is the author of more than 260 scientific publications.
 Dr. Pardoll is Seraph Professor of Oncology, Medicine, Pathology and Molecular Biology and Genetics at the Johns Hopkins University of Medicine. He is Co-Director of the Cancer Immunology Program in the Sydney Kimmel Comprehensive Cancer Center. Dr. Pardoll completed his M.D., Ph.D., Medical Residency and Oncology Fellowship at Johns Hopkins University. Dr. Pardoll has published over 200 papers as well as over 20 book chapters on the subject of T cell immunology and cancer vaccines. He has served on the editorial board of the Journal of the National Cancer Institute and Cancer Cell, and has served as a member of scientific advisory boards for the Cancer Research Institute, the University of Pennsylvania Human Gene Therapy Gene Institute, Biologic Resources Branch of the National Cancer Institute, Harvard-Dana Farber Cancer Center, Cerus Corporation, Global Medical Products Corporation, Genencor Corporation, Cell Genesys Corporation, Mojave Therapeutics, the American Association of Clinical Oncology and the American Association of Cancer Research. Dr. Pardoll has made a number of basic advances in cellular immunology, including the discovery of gamma-delta T cells, NKT cells and interferon-producing killer dendritic cells. Over the past two decades, Dr. Pardoll has studied molecular aspects of dendritic cell biology and immune regulation, particularly related to mechanisms by which cancer cells evade elimination by the immune system. He is an inventor of a number of immunotherapies, including GVAX cancer vaccines and Listeria monocytogenes-based cancer vaccines.
|